Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of “Moderate Buy” by Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts […]

Leave a Reply

Your email address will not be published.

Previous post Quisitive Technology Solutions, Inc. (CVE:QUIS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Next post Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from Brokerages